ArticleAnalytical chemistry2026
A Draft Map of E. coli Proteoforms.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Top-down proteomics (TDP) enables direct characterization of intact proteoforms, providing protein-level insights into molecular diversity arising from post-translational modifications and sequence variations. Despite this advantage, proteome coverage in TDP remains limited relative to bottom-up proteomics (BUP). To expand coverage, we developed an integrated multidimensional approach combining sequential protein extraction, size-exclusion chromatography (SEC) fractionation, and capillary zone electrophoresis (CZE)-tandem mass spectrometry (MS/MS) and reversed-phase liquid chromatography (RPLC)-MS/MS. This approach identified 743 proteoform families and 10,613 proteoforms from E. coli cells through hundreds of MS runs. By incorporating previous E. coli TDP data sets from our group, we identified 14,932 proteoforms from 985 proteoform families, covering 43% of the E. coli proteome. The data represent the highest proteome coverage of cells by MS-based TDP, creating a draft map of E. coli proteoforms. The results offer strong evidence that MS-based TDP can reach high proteome coverage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.